Compare · BDTX vs BIIB
BDTX vs BIIB
Side-by-side comparison of Black Diamond Therapeutics Inc. (BDTX) and Biogen Inc. (BIIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDTX and BIIB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $34.77B, about 347.8x BDTX ($100.0M).
- BIIB has hit the wire 4 times in the past 4 weeks while BDTX has been quiet.
- BIIB has more recent analyst coverage (25 ratings vs 13 for BDTX).
- Company
- Black Diamond Therapeutics Inc.
- Biogen Inc.
- Price
- -
- -
- Market cap
- $100.0M
- $34.77B
- 1M return
- -
- +6.27%
- 1Y return
- -
- +58.74%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 4
- Recent ratings
- 13
- 25
Black Diamond Therapeutics Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BDTX
- Director Behbahani Ali was granted 7,707 shares, increasing direct ownership by 8% to 110,236 units (SEC Form 4)
- Director Raman Prakash was granted 6,801 shares, increasing direct ownership by 15% to 51,840 units (SEC Form 4)
- Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
- SEC Form 10-Q filed by Black Diamond Therapeutics Inc.
- Black Diamond Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 4 filed by Director Behbahani Ali
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Menzel Garry E
- SEC Form 4 filed by Director Raman Prakash
Latest BIIB
- Biogen upgraded by Analyst with a new price target
- SEC Form 4 filed by Biogen Inc.
- Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
- Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
- Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
- Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
- A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
- Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- SEC Form 4 filed by Biogen Inc.